The time‐varying cardiovascular benefits of glucagon‐like peptide‐1 receptor agonist therapy in patients with type 2 diabetes mellitus: Evidence from large multinational trials

AIMS: To evaluate the time‐varying cardio‐protective effect of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using pooled data from eight contemporary cardiovascular outcome trials using the difference in the restricted mean survival time (ΔRMST) as the effect estimate. MATERIAL AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Deo, Salil V., Marsia, Shayan, McAllister, David A., Elgudin, Yakov, Sattar, Naveed, Pell, Jill P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540124/
https://www.ncbi.nlm.nih.gov/pubmed/35491516
http://dx.doi.org/10.1111/dom.14738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540124/
https://www.ncbi.nlm.nih.gov/pubmed/35491516
http://dx.doi.org/10.1111/dom.14738

Ejemplares similares